about
Immunotherapy in endometrial cancer - an evolving therapeutic paradigmPredicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasIdentification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQPTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG-2005) Retrospective Cohort Study (A STROBE-Compliant Article).MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer.Dual-specificity Phosphatase 1 Deficiency Induces Endometrioid Adenocarcinoma Progression via Activation of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase PathwayTubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.Emerging drugs in endometrial cancers.Immunotherapy in Gynecologic Cancers: Are We There Yet?Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.A molecular carrier to transport and deliver cisplatin into endometrial cancer cells.An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers.Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters.FOXC1, the new player in the cancer sandbox.Modeling Endometrial Cancer: Past, Present, and Future
P2860
Q27020910-7CB1A373-E42F-43A9-895C-8F52707F13F0Q27851999-65E21A57-4A4F-482A-92F5-FA282E983C6BQ28074769-02112339-08D3-418D-AE78-CA483F868E7AQ28743151-0B4F8472-8050-4E2D-86FC-5FB8E723AB6AQ35691011-CD8BD08E-BBA2-4018-B204-494E8C5D1E8FQ36746785-A0599E5C-4ECD-4D2B-9FDC-9736CD66A95EQ36822417-CBE30891-238C-4B03-A4B8-50C414C01B2DQ36827700-C5CB0BB9-7CEF-4AEC-A3BE-891355A07A0BQ36930125-FC94E7F9-2277-4D4E-978A-6370F78AAC3EQ36980135-FD08300A-B2EA-4CC9-BC0F-81A059645764Q37699264-0957B0C7-35D4-4DB9-A58B-636FA9C73968Q37786618-7C0726E6-DB7A-46B1-B2D9-131389B07406Q38608730-9D312843-89E7-414E-BA43-0D4F0F29B97FQ39164373-D8D7B8C4-F355-482C-ADF1-5D8BF08ECBFDQ39310876-3AD8BBFB-00DE-455E-9734-B384361E0BEBQ39409872-9F70DC9A-8C87-4F49-ABD7-0968BE8140B0Q47326692-427B09C4-3166-47D0-8BAE-C19FC8047856Q50976223-51AD0932-E59F-4251-B07F-863477FACB8DQ52682253-9AB3832F-A045-4AA1-BA20-774FA072859BQ57170070-A5D44D4E-623A-4E3C-A861-E07D2EC5D852
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment options for advanced endometrial carcinoma.
@en
Treatment options for advanced endometrial carcinoma.
@nl
type
label
Treatment options for advanced endometrial carcinoma.
@en
Treatment options for advanced endometrial carcinoma.
@nl
prefLabel
Treatment options for advanced endometrial carcinoma.
@en
Treatment options for advanced endometrial carcinoma.
@nl
P1433
P1476
Treatment options for advanced endometrial carcinoma.
@en
P2093
Don S Dizon
P304
P356
10.1016/J.YGYNO.2010.02.007
P407
P577
2010-03-12T00:00:00Z